There is abundant evidence that, worldwide, obesity and type 2 diabetes have dramatically increased over recent decades(Reference Zimmet, Alberti and Shaw1). Obesity is closely associated with insulin resistance and other chronic conditions, including dyslipidaemia, hypertension and CVD, all components of the metabolic syndrome(Reference Alberti and Zimmet2, Reference Zavaroni, Bonini, Fantuzzi, Dall'Aglio, Passeri and Reaven3). Tea, from Camellia sinensis, exists in three basic forms: fermented black tea; semi-fermented oolong tea; non-fermented green tea(Reference Cheng4). Due to inactivation of polyphenol oxidase, green tea is rich (up to 30 % of the dry leaf weight) in flavanols known as catechins(Reference Graham5). Catechins have been reported to have many biological effects, including anti-mutation(Reference Okuda, Mori and Hayatsu6), anti-carcinogenesis(Reference Yang and Wang7), anti-oxidation(Reference Sung, Nah, Chun, Park, Yang and Min8) and anti-angiogenesis(Reference Cao and Cao9) properties.
Research into the relationship between green tea and obesity-related insulin resistance syndrome has shown that green tea enhances in vitro insulin activity(Reference Anderson and Polansky10), enhances insulin sensitivity in human subjects(Reference Tsuneki, Ishizuka, Terasawa, Wu, Sasaoka and Kimura11) and rat(Reference Wu, Juan, Ho, Hsu and Hwang12), and reduces hypertriacylglycerolaemia in mice(Reference Sayama, Lin, Zheng and Oguni13). The main active component in green tea mediating these effects seems to be epigallocatechin gallate (EGCG)(Reference Kao, Hiipakka and Liao14, Reference Waltner-Law, Wang, Law, Hall, Nawano and Granner15).
Mechanisms explaining the effects of green tea and its components on obesity-related metabolic disturbances are not fully understood and some findings are contradictory. For example, one study reported that green tea decreased the translocation of the insulin-dependent GLUT4 in adipose tissue(Reference Ashida, Furuyashiki, Nagayasu, Bessho, Sakakibara, Hashimoto and Kanazawa16) while another(Reference Wu, Juan, Hwang, Hsu, Ho and Ho17) found an increasing effect of green tea on GLUT4 content of adipocytes. There are also conflicting findings on the relationship between green tea polyphenols and the important transcription factors involved in lipid and glucose homeostasis (PPARα(Reference Jiao, Ye and Zhao18, Reference Lee19) and PPARγ(Reference Ashida, Furuyashiki, Nagayasu, Bessho, Sakakibara, Hashimoto and Kanazawa16, Reference Li, Douglas, Maiyoh, Adeli and Theriault20)). Furthermore, many studies used high concentrations of catechins that may not reflect typical consumption.
Our laboratory has demonstrated that obesity in the dog produces a metabolic disorder nearly identical to that seen in the obese human subject(Reference Bailhache, Ouguerram, Gayet, Krempf, Siliart, Magot and Nguyen21, Reference Bailhache, Nguyen, Krempf, Siliart, Magot and Ouguerram22). Moreover, the dog genome has been sequenced(Reference Kirkness, Bafna and Halpern23) supporting use of the obese dog as a model to study human metabolic disorders and link these changes to molecular studies.
The purpose of the present study in dogs was to examine the effects of extended nutritional supplementation with green tea on insulin sensitivity and plasma lipid concentrations and to determine whether transcriptional changes occur in liver, skeletal muscle and/or visceral and subcutaneous adipose tissue. We measured the expression of PPARα and PPARγ in their specific tissues and the expression of target genes including lipoprotein lipase (LPL), adiponectin and GLUT4; LPL expression is mediated by both PPARα and PPARγ whereas adiponectin and GLUT4 expression is mediated only by PPARγ24.
Materials and methods
Animals and diet
The ten obese and insulin-resistant beagle dogs (neutered females) were all healthy adults (mean age 4 years) with a mean body weight of 14·2 (sem 0·4) kg (ideal body weight 10·1 (sem 0·2) kg). All had a body condition score of 7 or 8 on the 9-point scale(Reference Laflamme25). They were housed at the National Veterinary School of Nantes according to the regulations for animal welfare of the French Ministry of Agriculture and Fisheries. The experimental protocol adhered to European Union guidelines and was approved by the local Animal Use and Care Advisory Committee.
Before the study for a period of 6 months, the dogs were fed a single hyperenergetic meal each day comprising 28 g/kg of a dry commercially available and nutritionally complete diet (18 MJ metabolisable energy/kg, 32 % protein, 20 % fat) to induce obesity. The dogs continued to receive these rations throughout the 12-week study.
Obese and insulin-resistant dogs were randomly divided into two groups: a green tea group (n 6), a control group (n 4). For 12 weeks, the green tea group received a capsule of green tea extract (80 mg/kg per d: a nutritionally relevant, non-pharmacological dose) orally just before the daily meal, whilst the control group received an empty capsule. The freeze-dried green tea extract (Vitamin Shoppe, North Bergen, NJ, USA) contained: epicatechin 35·7 mg/g; epicatechin gallate 64·8 mg/g; epigallocatechin 20·2 mg/g; EGCG 153·1 mg/g. Body weight and food intake were monitored twice weekly.
Body composition
Body composition was determined using isotopic dilution before and after 12 weeks' supplementation. D2O (99·9 % D/H; Euriso-top, Gif-sur-Yvette, France) was injected subcutaneously following a 24 h fast, with jugular vein blood samples (into heparin) collected 5 h later. The whole blood was centrifuged (4°C, 2124 g for 10 min) and plasma deuterium concentration assessed (using Fourier transform IR spectroscopy; Brüker SA, Wissembourg, France).
Lipid profile
Jugular vein blood samples were collected once weekly (into EDTA) following a 24 h fast, for measurement of plasma TAG, total cholesterol (TC) and NEFA concentrations. Blood was immediately centrifuged (at 4°C, 2124 g for 10 min) and stored (at − 80°C) until further analysis.
Fast protein liquid chromatography analysis for lipoprotein separation was performed at room temperature using two P-500 pumps (1 Mpa), a MV-7 place multi-injection with a 200 μl loop, two Superose 6HR 10/30 columns in quick succession, a UV monitor UV-1, a FRAC-100 fraction collector and a LCC-501 Plus controller. The absorbance of the eluent was monitored continuously at 280 nm using a UV monitor. The system was controlled by FPLC DIRECTOR software (Amersham Pharmacia Biotech Inc., Orsay, France). Elution was performed in a 1 mm-EDTA, 154 mm-NaCl and 0·02 % NaN3 (pH 8·2) buffer. The buffer was filtered through a 0·22 μm filter (Membrane filters type GV; Duropore®, Millipore). The column was washed with an aqueous ethanol solution (20 %). Plasma (200 μl) was injected and elution was performed at a flow of 0·35 ml/min. The fractions were collected from 35 to 110 min and the columns were washed for 40 min at the end of each run. Fast protein liquid chromatography was programmed to collect elution volume from 10 ml to 40 ml, which represented seventy-five fractions of 350 μl and resolved three lipoprotein fractions: VLDL (fractions 3 to 11, elution volume 12·95 to 15·75 ml), to LDL (fractions 15 to 39, elution volume 17·15 to 25·55 ml), to HDL1 (fractions 40 to 61, elution volume 26·90 to 33·25 ml). These fractions were subsequently analysed for TAG and TC as described later.
Euglycaemic–hyperinsulinaemic clamp
In vivo insulin sensitivity was determined using a 3 h euglycaemic–hyperinsulinaemic clamp, performed following a 24 h fast both before and after 12 weeks' supplementation, as previously described(Reference Bailhache, Ouguerram, Gayet, Krempf, Siliart, Magot and Nguyen21). Briefly, hyperinsulinaemia was induced by infusing human insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) via a catheter placed into the cephalic vein (4 mU/kg for 1 min and 2 mU/kg per min for the duration of the experiment). Glucose (Glucose 20 %; Laboratoire Aguettant, Lyon, France) was clamped at basal level by adjustment of the glucose infusion rate in the cephalic vein. Blood samples were drawn from a jugular catheter every 5 min from 0 to 60 min and every 10 min from 60 to 180 min. These samples were placed in ice-cold heparinized tubes and centrifuged (at 4°C, 2124 g for 10 min) and stored (at − 80°C) until insulin analysis. Insulin sensitivity index was defined as the mean glucose infusion rate (mg/kg per min) divided by the mean plasma insulin (μU/ml) of the last 60 min of the clamp(Reference Beard, Bergman, Ward and Porte26).
Homeostasis model assessment of insulin resistance index
Homeostasis model assessment of insulin resistance (HOMA-IR) yields a formula for insulin resistance and derives from fasting insulin (I0 (mIU/l)) and glucose (G0 (mmol/l)) concentrations. This index is defined by:
Chemical analysis
Rapid determination of blood glucose during clamping was achieved using the glucose oxidase method (Glucotrend® Plus; Roche Diagnostics, Mannheim, Germany). Plasma insulin concentrations were measured using a commercial RIA kit (RIA Insik-5; Diasorin, Saluggia, Italy). TAG, TC and NEFA were analysed in plasma using enzymatic methods (Triglycérides enzymatiques PAP 150; BioMérieux, Marcy-l'Etoile, France, Cholesterol RTU; Biomérieux, Marcy-l'Etoile, France and NEFA C; WAKO, Oxoid, Dardilly, France).
RNA extraction
Visceral and subcutaneous adipose tissue and skeletal muscle and liver biopsies were obtained intraoperatively under anaesthesia, following a 24 h fast both before and after 12 weeks' supplementation. Skeletal muscle biopsies were removed from the tibialis anterior. Approximately 100 mg each tissue was cleaned in saline. TRIzol reagent (1 ml; Gibco BRL, Grand Island, NY, USA) was added and the tissue immediately frozen in liquid N. RNA was extracted from frozen tissues using TRIzol reagent according to the manufacturer's instructions. Total RNA concentration was quantified by spectrophotometric absorbance at 260 nm.
Reverse transcription and real-time PCR analysis
Total RNA (1 μg) was reverse-transcribed in a 20 μl reaction volume using random primers (Pharmacia, Saclay, Orsay Cedex, France) and Superscript II Moloney leukaemia virus RT (according to the manufacture's instructions; Life Technologies, Cergy Pontoise, France).
Quantitative real-time PCR was conducted with a rotorgene 2000 (Ozyme, Saint-Quentin en Yvelines, France) in a 20 μl mixture containing 1X SYBR Green (Roche Diagnostic, Meylan, France), 0·25 mm-dNTP, each primer (0·5 mm), 2 U Taq Titanium DNA polymerase (Ozyme) and 2 μl cDNA mixture of each sample. Glyceraldehyde-3-phosphate dehydrogenase was used as a reference for initial RNA loading. The sense/antisense primers (Genosys, Pampisford, UK) were designed using GeneJokey Software (Biosoft, Ferguson, MO, USA). The specificity of PCR primers and the annealing temperature were tested under normal PCR conditions with temperature gradient (55°C to 70°C) as annealing (Table 1).The real-time PCR conditions were 95°C for 300 s (to activate the hot start enzyme) followed by: (1) thirty-five cycles of 95°C for 5 s, 63°C for 10 s, 72°C for 10 s and 83°C for 15 s for PPARγ; (2) thirty-five cycles of 95°C for 5 s, 62°C for 15 s, 72°C for 15 s and 82°C for 15 s for PPARα; (3) forty cycles of 95°C for 5 s, 62°C for 15 s, 72°C for 15 s and 86°C for 15 s for the LPL; (4) forty-five cycles of 95°C for 5 s, 70°C for 15 s, 72°C for 15 s and 85°C for 15 s for GLUT4; (5) forty cycles of 95°C for 5 s, 69°C for 15 s, 72°C for 15 s and 86°C for 15 s for adiponectin; (6) thirty cycles of 95°C for 5 s, 69°C for 15 s, 72°C for 15 s and 86°C for 15 s for the glyceraldehyde-3-phosphate dehydrogenase. The fluorescence cycle threshold (Ct) was calculated to quantify the relative amount of gene expression. Results are expressed according to the 2− ΔΔCt method(Reference Livak and Schmittgen27). The level of expression before green tea supplementation was arbitrarily set at 100 %.
Sense/antisense primers used for glyceraldehyde-3-phosphate deshydrogenase (GAPDH), PPARα, PPARγ, adiponectin, lipoprotein lipase (LPL) and GLUT4 relative quantification and annealing temperatures determined for each PCR primer*
* For details of procedures, see Materials and methods.
Statistical analysis
Data are expressed as means with their standard errors of the mean. The statistical analysis used Stat View 5.0 software (SAS Institute, Cary, NC, USA). Comparison among means was performed by Student's t test for paired values. A P value < 0·05 was considered to be significant.
Results
Body weight, food intake and body composition
There was no significant difference from baseline in either group in terms of body weight or food intake at any time point. The mean values of the food intake during the 12 weeks of treatment was 578 (sem 29) kJ/kg0·75 in the green tea group and 578 (sem 25) kJ/kg0·75 in the control group. At 12 weeks (after treatment), there was no difference from baseline (week 0, before treatment) in body fat mass in either group (Table 2).
Body weight and body composition of the 12 weeks' green tea-supplemented and control obese dogs* (Values are presented as means with their standard errors)
There was no significant difference between week 0 (before treatment) and week 12 (after treatment) of the protocol in either group.
* For details of animals and procedures, see Materials and methods.
Insulin sensitivity
The euglycaemic–hyperinsulinaemic clamp data (fasting glucose and insulin, plateau of insulin level, glucose infusion rate and insulin sensitivity index) in normal-weight and obese dogs before and after treatment in the green tea group and in the control group are shown in Table 3.
Fasting insulin and glucose concentrations, plateau of insulin level, glucose infusion rate (Ginf) and insulin sensitivity index (IIS) during the clamp in green tea group and control group at the normal weight state and at the obese state before and after treatment‡ (Values are presented as means with their standard errors)
*P < 0·05; **P < 0·01 v. before treatment.
†P < 0·05; †††P < 0·001 v. normal weight state.
‡ For details of animals and procedures, see Materials and methods.
Basal glycaemia did not significantly change when dogs became obese in either group (green tea and control). Also, basal glycaemia did not significantly change after treatment compared with baseline (before treatment) in either group. Basal insulinaemia tended to increase when dogs became obese and to decrease after green tea treatment but these changes were not significant. During the clamps, plateau of insulin level increased when the dogs became obese in both groups and tended to decrease after green tea treatment. Glucose infusion rate needed to maintain euglycaemia under hyperinsulinaemic conditions was lower in obese dogs than in normal dogs (P < 0·001) in either group and was elevated after green tea treatment (P < 0·05). Consequently, insulin sensitivity index was markedly decreased when dogs became obese ( − 59 (sem 12) % in the green tea group and − 73 (sem 15) % in the control group compared with normal weight state, P < 0·001). Insulin sensitivity index was markedly increased by green tea supplementation (by 60 (sem 11) % compared with baseline (before treatment; P < 0·01), whereas no change was observed in the control group.
HOMA-IR index tended to increase when the dogs became obese (3·58 (sem 0·73) v. 4·68 (sem 0·76) in the green tea group and 3·35 (sem 0·81) v. 4·14 (sem 1·03) in the control group) and to decrease after green tea treatment (4·68 (sem 0·76) v. 3·75 (sem 0·55)). However these changes are not significant.
Plasma lipid concentration
Lipid parameter data are summarized in Table 4.
Fasting plasma TAG, total cholesterol (TC), NEFA, VLDL-TAG, LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) in green tea group and control group at the normal weight state and at the obese state before and after treatment‡ (Values are presented as means with their standard errors)
NA, not available.
**P < 0·01 v. before treatment.
†P < 0·05; †††P < 0·001 v. normal weight state.
‡ For details of animals and procedures, see Materials and methods.
Diet-induced obesity increased plasma TAG and NEFA by respectively 71 (sem 19) % (P < 0·001) and 44 (sem 10) % (P < 0·05) in the green tea group and by 95 (sem 23) % (P < 0·05) and 43 (sem 15) % (P < 0·05) in the control group. TC concentrations did not change when dogs became obese in either group.
Plasma TAG ( − 48 (sem 8) % compared with baseline (before treatment; P < 0·01) and VLDL-TAG were reduced by green tea supplementation, whereas no change was observed in the control group. There was no significant difference from baseline (before treatment) in plasma NEFA, TC, LDL-cholesterol and HDL-cholesterol concentrations in either group. However, plasma NEFA tended to decrease after green tea treatment, whereas plasma NEFA tended to increase in the control group.
mRNA expression of PPARγ, lipoprotein lipase, adiponectin and GLUT4 in visceral and subcutaneous adipose tissue
The expression of the reference gene did not significantly change in visceral and subcutaneous adipose tissue between the beginning (week 0) and the end (week 12) of the treatment (data not shown).
Compared with baseline, expression of PPARγ, LPL, adiponectin and GLUT4 mRNA in visceral adipose tissue (n 6) was dramatically elevated after 12 weeks of green tea supplementation. Expression was approximately 2-fold greater for PPARγ (P < 0·05) and LPL (P < 0·05) and 4-fold greater for adiponectin (P < 0·05) and GLUT4 (P < 0·05), whereas no change was seen in the expression of any of these genes in the control group (n 4) (Fig. 1). Interestingly, in the subcutaneous adipose tissue of green tea-supplemented dogs (n 6), PPARγ, LPL, adiponectin and GLUT4 mRNA expression was increased by a similarly great extent (3-fold, 10-fold, 6-fold and 3-fold, respectively, P < 0·05; Fig. 2) compared with baseline.
Relative expression of (a) PPARγ, (b) lipoprotein lipase (LPL), (c) adiponectin and (d) GLUT4 mRNA in visceral adipose tissue of 12 weeks' green tea-supplemented (■; n 6) and control (□; n 4) obese dogs. Values are presented as means with their standard errors. *P < 0·05 v. baseline (week 0). For details of animals and procedures, see Materials and methods.
Relative expression of (a) PPARγ, (b) lipoprotein lipase (LPL), (c) GLUT4 and (d) adiponectin mRNA in subcutaneous adipose tissue of 12 weeks' green tea-supplemented (■; n 6) and control (□; n 4) obese dogs. Values are presented as means with their standard errors. *P < 0·05 v. baseline (week 0). For details of animals and procedures, see Materials and methods.
mRNA expression of PPARα and lipoprotein lipase in liver
The expression of the reference gene did not significantly change in liver between the beginning (week 0) and the end (week 12) of the treatment (data not shown).
In liver, the mRNA expression of PPARα, and its target gene, LPL, remained unchanged in both groups (Fig. 3).
Relative expression of (a) PPARα and (b) lipoprotein lipase (LPL) mRNA in the liver of 12 weeks' green tea-supplemented (■; n 6) and control (□; n 4) obese dogs. Values are presented as means with their standard errors. For details of animals and procedures, see Materials and methods.
mRNA expression of PPARα, lipoprotein lipase and GLUT4 in skeletal muscle
The expression of the reference gene did not significantly change in skeletal muscle tissue between the beginning (week 0) and the end (week 12) of the treatment (data not shown).
In skeletal muscle, green tea supplementation markedly increased the expression of PPARα (by 100 (sem 18) %, P < 0·01) and LPL (by 270 (sem 43) %, P < 0·01), but not GLUT4, compared with baseline (Fig. 4).
Relative expression of (a) PPARα, (b) lipoprotein lipase (LPL) and (c) GLUT4 mRNA in skeletal muscle of 12 weeks' green tea-supplemented (■; n 6) and control (□; n 4) obese dogs. Values are presented as means with their standard errors. **P < 0·01 v. baseline (week 0). For details of animals and procedures, see Materials and methods.
Discussion
In the present study, we have shown that 12 weeks' green tea supplementation in obese insulin-resistant dogs increases insulin sensitivity, decreases plasma TAG concentrations and increases expression of PPARα, PPARγ and their target genes LPL, GLUT4 and adiponectin. Body weight and fat mass were not affected.
Many previous human studies used high concentrations of catechins(Reference Li, Douglas, Maiyoh, Adeli and Theriault20, Reference Klaus, Pultz, Thone-Reineke and Wolfram28) that may not reflect typical consumption. A 2·5 % (w/v) tea concentration in 227 ml water represents the typical strength of brews consumed by human individuals and may contain approximately 340 mg catechins(Reference Bu-Abbas, Dobrota, Copeland, Clifford, Walker and Ioannides29). Thus, based on metabolic body weight (BW0 ·75), the consumption of green tea catechins by the dogs in the current study was nutritionally relevant and non-pharmacological, being equivalent to three cups of tea in human individuals. Dogs readily absorb EGCG (approximately 20 % of the dose) after oral administration(Reference Swezey, Aldridge, LeValley, Crowell, Hara and Green30); it is then distributed widely to a variety of epithelial tissues.
Very few studies have been reported regarding the in vivo effects of green tea or its catechins on insulin sensitivity(Reference Tsuneki, Ishizuka, Terasawa, Wu, Sasaoka and Kimura11, Reference Li, Douglas, Maiyoh, Adeli and Theriault20, Reference Ryu, Lee, Lee, Kim, Seo, Kim, Kim, Baik, Choi and Choi31). Moreover, these studies used glucose tolerance tests rather than the gold standard for assessing insulin sensitivity(Reference Radziuk32). In the present study, euglycaemic hyperinsulinaemic clamps showed a strong effect of green tea extract in improving insulin sensitivity in obese, insulin-resistant dogs. Fasting insulin concentrations have tended to increase when the dogs became obese and to decrease after green tea treatment. However, basal insulin and glucose concentrations did not significantly change. We have compared our clamp results with the data of HOMA-IR index, a simpler method to measure insulin sensitivity usually used in clinical and epidemiological studies when only fasting insulin and glucose values are available. We have found that HOMA-IR index tended to increase when the dogs became obese and to decrease after green tea treatment. The changes did not reach the statistical significance level probably due to the small sample size.
To understand the mechanisms that could explain these effects of green tea on insulin sensitivity, we examined the expression of proteins involved in glucose metabolism in visceral and subcutaneous adipose tissue and skeletal muscle. We showed that GLUT4 was markedly increased in visceral and subcutaneous adipose tissues, but not in skeletal muscle, after 12 weeks of green tea supplementation. The insulin-dependent GLUT4, located in muscle cells and adipocytes, increases the utilization of glucose by these tissues(Reference Park, Choi, Choi, Ryu, Jung and Lee33). Abel and colleagues presented convincing evidence that insulin resistance was initiated in adipose tissue and that adipose tissue may play a pivotal role in the induction of insulin resistance in muscle and liver(Reference Abel, Peroni, Kim, Kim, Boss, Hadro, Minnemann, Shulman and Kahn34). This would explain why, in the present study, green tea increased GLUT4 expression in adipose tissue but not in skeletal muscle. We have not examined the translocation of GLUT4 from intracellular storage sites to the plasma membrane. Thus, it is possible that green tea increases GLUT4 translocation and not GLUT4 expression in muscle cells.
The current results also showed that green tea increases adiponectin expression in both types of adipose tissue. Adiponectin is strongly inversely correlated to insulin resistance and improves insulin sensitivity by repressing gluconeogenesis and favouring glucose and NEFA oxidation by muscle(Reference Mlinar, Marc, Janez and Pfeifer35).
Other mechanisms could explain the effects of green tea catechins on obesity-related insulin resistance. EGCG increases tyrosine phosphorylation of the insulin receptor and insulin receptor substrate 1(Reference Waltner-Law, Wang, Law, Hall, Nawano and Granner15). It has also been suggested that tea catechins could lower glucose absorption in the intestinal tract by inhibiting its specific transporters(Reference Kobayashi, Suzuki, Satsu, Arai, Hara, Suzuki, Miyamoto and Shimizu36).
There have been several epidemiological and clinical investigations of the effects of green tea on plasma lipids in human subjects(Reference Ryu, Lee, Lee, Kim, Seo, Kim, Kim, Baik, Choi and Choi31, Reference Kono, Shinchi, Wakabayashi, Honjo, Todoroki, Sakurai, Imanishi, Nishikawa, Ogawa and Katsurada37, Reference Tokunaga, White, Frost, Tanaka, Kono, Tokudome, Akamatsu, Moriyama and Zakouji38), with contradictory findings. In rodents, Sayama and co-workers(Reference Sayama, Lin, Zheng and Oguni13) found a TAG-lowering effect of green tea and no change in plasma TC concentrations, whereas Ashida and colleagues(Reference Ashida, Furuyashiki, Nagayasu, Bessho, Sakakibara, Hashimoto and Kanazawa16) reported that green tea supplementation decreased TC, LDL-cholesterol, HDL-cholesterol and NEFA levels with no change in TAG concentrations. The present study found a marked decrease in plasma TAG concentrations in the green tea group related to a decrease in VLDL-TAG. However, no difference was observed in the cholesterol profile or NEFA levels.
LPL is an enzyme that hydrolyses circulating TAG-rich lipoproteins(Reference Schoonjans, Peinado-Onsurbe, Lefebvre, Heyman, Briggs, Deeb, Staels and Auwerx39). To explain the hypertriacylglycerolaemic effect of green tea, we measured LPL mRNA expression. Our results showed for the first time that LPL expression was dramatically elevated in visceral and subcutaneous adipose tissues, and in skeletal muscle, by green tea supplementation. It has been shown that EGCG is a potent inhibitor of apoB100 secretion(Reference Yee, Wang, Agdinaoay, Dang, Chang, Grandinetti, Franke and Theriault40), possibly through microsomal transfer protein inhibition, as demonstrated in vitro for other flavonoids(Reference Allister, Borradaile, Edwards and Huff41). Furthermore, EGCG promotes the accumulation of TAG in cytosolic lipid droplets, thereby diverting lipids from the assembly of VLDL to storage in the cytosol(Reference Li, Stillemark-Billton and Beck42). In vivo measurement of the processes involved in VLDL metabolism, particularly apoB100 and LPL activity, would be required to explain the hypotriacylglycerolaemic effects of green tea.
PPAR are transcription factors for the genes involved in glucose and lipid homeostasis, including LPL, adiponectin and GLUT4. Three isotypes of PPAR have been identified (α, γ, β/δ). The amino acid sequence of the ligand binding domain of PPARα in the dog was found to be 97 % identical to that of man. PPARα is predominantly expressed in tissues with a high rate of fat catabolism (e.g. liver and muscle). The expression of PPARγ is high in adipose tissue, where it triggers adipocyte differentiation and induces the expression of genes critical for adipogenesis (for review see(Reference Desvergne and Wahli24)). We have shown that green tea increases PPARα expression in skeletal muscle (but not in liver) and increases PPARγ expression in visceral and subcutaneous adipose tissues.
Tea catechins activated PPARα in cell culture(Reference Lee19) and increased PPARα and PPARγ expression in hamster liver(Reference Li, Douglas, Maiyoh, Adeli and Theriault20). The use of fenofibrate(Reference Gebel, Arand and Oesch43) and other PPARα activators(Reference Sterchele, Sun, Peterson and Vanden Heuvel44) showed that the induction of PPARα mRNA might be a property shared by all members of this class of chemical. Moreover, Davies et al. (Reference Davies, McFie, Khandelwal and Roesler45) showed that the ability of troglitazone, a thiazolidinedione, to up regulate PPARγ could be due to its antioxidant properties. Green tea catechins are potent antioxidants(Reference Sung, Nah, Chun, Park, Yang and Min8) and, thus, could act similarly. Antioxidants (via intracellular redox state) could regulate the transcription factors, NF-κB and activator protein-1(Reference Sen and Packer46), and PPARγ could be regulated by these transcription factors(Reference Wang, Anderson, Chen, Paulsson, Sjogren and Li47). Given the increase in the expression of PPARα and PPARγ and their target genes in their specific tissues, we hypothesize that tea catechins might represent new PPAR activators.
Clinical studies have shown that body weight and fat mass of human subjects and animals given green tea catechins decreased significantly(Reference Klaus, Pultz, Thone-Reineke and Wolfram28, Reference Nagao, Komine, Soga, Meguro, Hase, Tanaka and Tokimitsu48). In the present study, body weight and body composition were not affected by green tea supplementation. During treatment, our dogs were fed approximately according to the National Research Council recommendation for maintenance, which could explain why body weight remains stable in the green tea and control groups. An elevation of the expression of PPARγ, LPL and GLUT4 in adipose tissue, without any effect on plasma NEFA concentration, would enhance fat depots – similar to thiazolidinedione(Reference Fonseca49). An increase in uncoupling protein activity in adipose tissue might regulate the energy balance by uncoupling mitochondrial respiration – as has been shown with thiazolidinedione(Reference Cortright, Zheng, Jones, Fluckey, DiCarlo, Grujic, Lowell and Dohm50). Some reports suggested that green tea catechins not only promote energy expenditure but also stimulate the oxidation of lipids by the known inhibitory effect of catechins and notably EGCG on catechol-O-methyltransferase, an enzyme that degrades noradrenaline(Reference Dulloo, Seydoux, Girardier, Chantre and Vandermander51). Taken together, we can hypothesize that green tea catechins enhance lipid catabolism, which could counteract the PPARγ agonist-induced lipogenesis. This could explain the absence of change in body composition after green tea treatment. Green tea catechins could trigger a shift of fat distribution from visceral to subcutaneous adipose depots as has been shown with a PPARγ agonist, the pioglitazone(Reference Miyazaki, Mahankali, Matsuda, Mahankali, Hardies, Cusi, Mandarino and Defronzo52). It is well known that visceral adipocytes are lipolytically more active than subcutaneous fat cells and removal of visceral fat enhances insulin sensitivity(Reference Abel, Peroni, Kim, Kim, Boss, Hadro, Minnemann, Shulman and Kahn34).
In conclusion, the present results demonstrate that extended nutritional supplementation with green tea may reverse obesity-related metabolic disturbances by improving insulin sensitivity and decreasing VLDL-TAG concentrations. We also observed an increase in the expression of PPARα and PPARγ, important transcription factors involved in lipid and glucose homeostasis. The mRNA expression of their target genes (LPL, adiponectin and GLUT4) was increased and could explain the beneficial effects of green tea in obese, insulin-resistant dogs. According to previous studies(Reference Lee19, Reference Li, Douglas, Maiyoh, Adeli and Theriault20), these results suggest that green tea (or its catechins) may be new natural PPAR activators. The obese, insulin-resistant dog model can thus be used, in further studies, to assess the in vivo effects of EGCG, which is the principal – and probably the most active – catechin in green tea.
Acknowledgements
The authors are grateful to Samuel Ninet, Gérald Pondevie and Philippe Bleis for taking care of the animals and for technical assistance. None of the authors has financial or personal conflicts of interest with regard to this study.
